Given the enormous contribution of anxiety disorders to the burden of disease, it is key to optimize their prevention and treatment. In this critical review we assess advances in the pharmacotherapy of anxiety disorders, as well as remaining challenges. In recent decades, the field has seen rigorous clinical trial methods to quantify the efficacy and safety of serendipitously discovered agents, more focused development of medications with selective mechanisms of action, and the gradual translation of insights from laboratory research into proof-of-principle clinical trials. On the positive side, a considerable database of studies shows efficacy and relative tolerability of the selective serotonin reuptake inhibitors in the major anxiety disorders, and secondary analyses of such datasets have informed questions such as optimal definition of response and remission, optimal dose and duration, and comparative efficacy of different agents. Significant challenges in the field include barriers to appropriate diagnosis and treatment of anxiety disorders, failure of a significant proportion of patients to respond to first-line pharmacotherapy agents, and a limited database of efficacy or effectiveness studies to guide treatment in such cases.
nosis and treatment of anxiety disorders, failure of a significant proportion of patients to respond to first-line pharmacotherapy agents, and an ongoing lack of data on a number of key questions. In this paper we provide a critical review of the pharmacotherapy of anxiety disorders, summarizing advances in the field, as well as pointing out some of the areas that need to be addressed in future work.
Generalized anxiety disorder
In many ways, developments in the pharmacotherapy of generalized anxiety disorder (GAD) reflect the history of the field of anxiety disorders as a whole. Anxiety is a symptom that has been present since the beginning of time, and anxiolytic agents have long been part of the armamentarium of traditional healers and early physicians. The effects of early medications were discovered serendipitously, they sometimes had a poor risk:benefit ratio (eg, the barbiturates), and trials were either nonexistent or limited by methodological problems including a lack of reliable diagnostic criteria and valid measures of symptom severity. The introduction of benzodiazepines and tricyclic antidepressants (TCAs) was an important advance in the pharmacotherapy of GAD; these agents were studied in rigorous randomized controlled trials, and were shown to have an acceptable risk:benefit ratio. 3 Subsequent work with agents that targeted particular molecular systems, such as the selective serotonin reuptake inhibitors (SSRIs) and the serotonin and noradrenaline reuptake inhibitors (SNRIs), constituted another important step, insofar as the quality of trials and risk:benefit ratio further improved. [4] [5] [6] [7] (Table I) . Indeed, most current treatment guidelines emphasize that SSRIs and SNRIs are the first-line pharmacotherapy agents of choice in GAD. [8] [9] [10] [11] Finally, more recent ongoing basic and clinical psychobiology research has led to novel molecular targets for future development. [12] [13] [14] As their name suggests, SSRIs inhibit the reuptake of serotonin at the presynaptic membrane by the serotonin (5-HT) transport pump, thus increasing synaptic concentration of the neurotransmitter. SSRIs currently available for clinical use are citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. There is evidence to support the efficacy and tolerability of escitalopram, fluoxetine, paroxetine, and sertraline in the short and longer-term management of GAD, 7, 8 and both escitalopram and paroxetine have FDA approval for this indication. 15 Clinical trials have studied paroxetine 20 to 50 mg/day and escitalopram 10 to 20 mg/day, 5 but in practice patients can be started on even low doses and titrated up (for example an initial paroxetine dosage of 10 mg/day, titrated upwards every 7 days, may be used, Table I ). 16 TCAs inhibit reuptake of both noradrenaline and serotonin, but also act on a range of other neurotransmitter systems, accounting for their relatively poor safety and tolerability profile. Venlafaxine and duloxetine are SNRIs which act selectively to inhibit reuptake of noradrenaline and serotonin. The use of both agents in the short-term management of GAD is supported by a number of RCTs, 6, 7 and venlafaxine was the first antidepressant to receive FDA approval for the treatment of GAD. 16 Venlafaxine studies used an initial dosage of 37.5 mg or 75 mg, which was then titrated up to a maximum of 225 mg; duloxetine studies ranged from 60 to 120 mg. [17] [18] [19] There are relatively few maintenance studies of SSRIs and SNRIs in the longer-term treatment of GAD. 7 However, such trials have consistently indicated that early discontinuation of these agents is associated with a high risk of relapse. Thus, most treatment guidelines suggest that after a response to pharmacotherapy is obtained, treatment should be continued for at least a year, and that discontinuation should be done gradually. 3, [9] [10] [11] Agomelatine is a melatonergic agonist (MT 1 and MT 2 receptors) and 5HT 2C antagonist that is registered for treatment of depression by the European Medical Agency. There are also several lines of evidence suggesting that agomelatine may be effective in GAD. First, this agent demonstrates anxiolytic activity in various rodent models. 20 Second, it reduces anxiety symptoms in patients with depression. 21 Finally, agomelatine 25 to 50 mg/day was found efficacious in a recent trial in GAD. 22 Remarkably, agomelatine was as well tolerated as the placebo, and patients suffered no discontinuation emergent symptoms. Initial data from a relapse prevention trial are also promising. 23 Benzodiazepines exert their anxiolytic effect by binding to a specific site on the γ-aminobutyric acid (GABA)-receptor, thus potentiating the effect of the inhibitory neurotransmitter GABA. A number of randomized controlled trials support the use of these agents in the shortterm treatment of GAD, 24 and alprazolam is FDA-P h a r m a c o l o g i c a l a s p e c t s approved for the treatment of GAD. 15 A recent metaanalysis found that the efficacy of benzodiazepines was comparable to that of the SSRIs and venlafaxine in the treatment of GAD. 25 However, although the benzodiazepines have the advantage of a particularly early onset of action (sometimes within 15 to 60 minutes), higher dosages of these agents may be associated with a number of adverse effects, including sedation, physical dependence, and impaired concentration. 16 Furthermore, they are ineffective for treating comorbid depression, and may be less effective for treating the psychic than the somatic symptoms of GAD. 26 Long-term use of these agents may be associated with problematic withdrawal symptoms and rebound anxiety. 16 Thus most treatment guidelines do not recommend benzodiazepines as a first-line pharmacotherapy in GAD. [8] [9] [10] [11] Buspirone is a partial agonist of the 5-HT 1A receptor.
Although there is evidence of good efficacy and tolerability in GAD, 27 clinicians remain somewhat sceptical of its utility, perhaps because of relatively unfavorable reports of its value from patients previously exposed to benzodiazepines. Given the evidence base, buspirone may certainly be considered in the treatment of patients with GAD, and on theoretical grounds this agent may have a particularly useful role in those with comorbid alcohol dependence (where benzodiazepines are partially contraindicated) 28 and in the augmentation of SSRIs in treatment-refractory GAD. 29 Gabapentin and pregabalin are structurally analogous to GABA and bind to the α 2 δ subunit of the voltagegated calcium channels in the CNS. They exert their effects by increasing glutamic acid decarboxylase activity, thus also increasing levels of neuronal GABA and inhibiting the release of excitatory neurotransmitters such as glutamate, noradrenaline, and substance P. 30 A number of randomized, placebo-controlled trials have demonstrated efficacy and tolerability of pregabalin over the short term, and pregabalin was effective in preventing symptom relapse. 30 Pregabalin was also found to be efficacious and well-tolerated in elderly patients with GAD. 31 The relatively favorable side-effect profile of pregabalin makes it another useful treatment option in GAD. 7 Current treatment guidelines recommend a dose range of 150 to 600 mg/day for adult patients. 9 Antipsychotic agents have also been studied as monotherapy in GAD. There is evidence that the atypical antipsychotic quetiapine is more effective than placebo in improving clinical response and remission rates in patients with GAD. 32, 33 However, risk:benefit ratio remains a concern given the possibility of adverse events such as metabolic syndrome. On the other hand, these agents may have a role to play in treatment-refractory patients, with evidence suggesting that various antipsychotic agents may be beneficial as augmentation strategies in those with treatment-refractory GAD. 34, 35 Indeed, in clinical practice a significant proportion of patients with GAD fail either to receive appropriate therapy or to respond to first-line pharmacotherapy. An immediate step in the management of the latter group of patients is to ensure that diagnosis is correct, that psychiatric and medical comorbidity has not been overlooked, and that the trial is of sufficient duration and dosage. 36 Next steps include switching to a different agent, or augmentation. 8, 9, 16, 37 There are few switch studies in GAD, but the literature on depression suggests that a different SSRI or an agent from a different class might be useful in refractory cases. Pharmacotherapy augmentation strategies include the addition to SSRI/SNRI treatment of buspirone, 29 pregabalin, 38 or low doses of atypical antipsychotics. 35, 34 Although data on the value of combined pharmacotherapy and psychotherapy in GAD is surprisingly limited, 39 psychotherapy augmentation strategies may also be considered. In addition to the glaring absence of data on how best to approach the treatment-refractory GAD patient, a number of other gaps in the literature deserve to be highlighted. First, most treatment data on GAD derive from trials of GAD patients without comorbidity recruited by academic centers; there are few data on effectiveness in real-world settings, where the vast majority of patients with GAD present, often with a range of comorbid psychiatric and medical disorders and symptoms. Second, there are relatively few data on "special" populations, including children and adolescents and geriatric patients with GAD, 40, 41 or on whether early pharmacotherapy of GAD is able to prevent subsequent onset of mood and substance-use disorders.
42
Several promising future lines of investigation of GAD have, however, been opened up by ongoing work on the psychobiology of GAD. Work on the role of the glutamate system in fear extinction, 43 on the role of neuropeptides in stress responses, 44 and on a range of second messenger or other downstream systems, 45, 46 for example, may ultimately lead to new treatments for GAD. The development of a personalized approach to the pharmacotherapy of GAD will depend ultimately on the incorporation of genetic and/or imaging methodologies into research on the pharmacotherapy of GAD; surprisingly little such work has been done to date, and much more is therefore needed.
Obsessive-compulsive disorder
The serendipitous discovery that clomipramine (CMI), a more serotonergic tricyclic, is effective for obsessivecompulsive disorder (OCD) was important in giving impetus to a serotonin hypothesis of OCD. 47 Subsequent work found that the more selective SSRIs were not only efficacious but also well-tolerated. 48 More recent psychobiological research has focused on delineating the role of neurotransmitters other than serotonin; dopaminergic augmentation strategies have been used clinically for some time now, 49 and a range of other molecular treatment targets are being pursued. 50, 51 Anecdotal reports of the efficacy of CMI in OCD were followed by rigorous randomized controlled trials. Such work demonstrated that clomipramine was more efficacious than both placebo and noradrenergic tricyclic agents such as desipramine, and that it was efficacious in both adults as well as in children and adolescents with OCD. 52 Such work led to the first FDA approval for OCD pharmacotherapy. 15 The use of intravenous (IV) CMI for refractory OCD has also been investigated, 53, 54 as this route of administration avoids first-pass hepatic P h a r m a c o l o g i c a l a s p e c t s metabolism which breaks CMI down to its less potent form, desmethyl-clomipramine. With the introduction of the SSRIs, several studies of these agents were undertaken in OCD, and these generally showed efficacy and safety. 55 Fluoxetine, fluvoxamine, paroxetine, and sertraline have all been FDAapproved for OCD. 56 While several meta-analyses have suggested that CMI may be more effective than SSRIs (Table II) , 57 this finding may reflect the fact that early studies were characterized by a lower placebo response rate. Head-to-head comparisons of CMI and SSRIs have shown equal efficacy and superior tolerability for the SSRIs. 58 Thus, the SSRIs are now typically viewed as the first-line choice for OCD. 8, 9, 11, 56, 59 A meta-analysis of medication dosage findings in OCD suggests that patients who fail to respond to low-dose therapy should be increased to a higher dose. 60 An adequate trial in OCD should be at least 12 weeks in length. 61 Although there is less published work on the longer-term treatment of OCD, a number of studies have demonstrated that early discontinuation often leads to relapse. 58 Guidelines therefore suggest that patients who respond to initial acute treatment should then be continued for at least 1 year, and withdrawn gradually. 8, 9, 56, 59 It has been suggested that efficacy can be maintained even after a reduction in dosage of longterm treatment, with the benefits of improved tolerability and adherence. 62 Unfortunately, up to 50% of patients with OCD treated with an adequate trial of SSRI fail to respond fully. 63 Basic work on the psychobiology of OCD has suggested that neurotransmitters other than serotonin may be important in its pathogenesis. Indeed, the best studied SSRI-augmenting agents in OCD are low-dose atypical antipsychotics. Early work suggested that these were particularly useful in patients with comorbid tics, 64 but subsequent work has indicated that they may be useful in both patients with and without tic disorders. 65, 66 More recently, evidence for the role of the glutamatergic system in mediating OCD has emerged, and there has been interest in using glutamate-modulating drugs in the augmentation of treatment-resistant OCD. The anticonvulsant agent topiramate, which inhibits glutamatergic neurotransmission, may be useful in treatmentrefractory OCD. 67 Riluzole, which inhibits the release of glutamic acid, thus also blocking glutamatergic neurotransmission, has been found effective in proof of principle trials. 68, 69 Memantine, another glutamatergic agent, may also be useful in treatment-refractory OCD. 70 There has also been interest in using the NMDA partial agonist, cycloserine, in combination with CBT in OCD. 71 Several other somatic treatment options in OCD are also being explored. First, a range of other mechanisms have been targeted by SSRI-augmentation strategies, including use of the 5-HT 3 receptor antagonist, ondansetron. 72 Second, given the abundance of literature on autoimmu- Serotonin reuptake inhibitors (SRIs) SRIs have a significant benefit, with clomipramine more effective than fluoxetine. nity in OCD, one strand of work has focused on the use of immunoglobulins and plasmapheresis in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). [73] [74] [75] Third, given the work on the neural circuitry of OCD, neurosurgery to remove specific lesions 76 or deep brain stimulation after implantation of electrodes has been investigated. 77, 78 Such approaches provide promise for the future management of refractory OCD.
Panic disorder
Research on the pharmacotherapy of panic disorder (PD) was given significant impetus by the early serendipitous finding that tricyclic antidepressants are effective, and the hypothesis that different pharmacological agents are effective for different anxiety disorders. 79 Subsequent research done in order to register alprazolam and other benzodiazepines for the treatment of panic disorder did not provide a great deal of support for this hypothesis, but was important in contributing to the development of clinical trial methods in this condition. Subsequent rigorous randomized controlled trials of the SSRIs in PD were again an important advance insofar as they provided an effective and relatively welltolerated treatment option. [80] [81] [82] As in the case of GAD and OCD, however, much further work is required to optimize the treatment of refractory cases. Fortunately, ongoing studies of the psychobiology of PD have provided several leads which may be helpful in developing more targeted therapies in the future. 80 Early work on tricyclic agents such as imipramine and clomipramine demonstrated that these agents were efficacious in PD, reducing the frequency of panic attacks and the severity of anticipatory anxiety. 80 These older agents appear as effective as more recent antidepressant agents. 83 However, the widespread use of these agents is limited by their relatively unfavorable side-effect profile, including problematic anticholinergic and antiadrenergic effects, 84 and they are not recommended as first-line agents. [8] [9] [10] [11] Similarly, while classic monoamine oxidase inhibitors (MAOIs) may be effective for panic disorder, they are not commonly prescribed for this indication. These agents exert their antidepressant effect by inhibiting the MAO enzyme, so decreasing the breakdown of serotonin and noradrenaline and increasing the net level of these neurotransmitters in the CNS. 15 However, as is the case with TCAs, the widespread use of MAOIs is generally limited by their associated adverse effects (including the risk of hypertensive crisis when taken with tyramine-containing foods) and their numerous potential drug interactions. Alprazolam, a short-acting agent, is the best studied benzodiazepine in panic disorder. 80 It has shown efficacy compared with placebo in short and longer-term studies, and it has been found comparable in effect to the tricyclics and to the SSRIs. 85 Alprazolam as well as a number of other benzodiazepines (clonazepam, diazepam, and lorazepam) are FDA-approved for PD. 15 Nevertheless, once again, given their relatively unfavorable side-effect profile, most treatment guidelines do not list these agents as a first-line option. [8] [9] [10] [11] Fluoxetine, paroxetine, and sertraline have all been rigorously investigated in clinical trials and have received FDA approval for use in PD. 15 They are as effective, but better tolerated, than the older TCAs. 83 There seems to be little difference in efficacy within this group of agents. 80 Current guidelines recommend that active medication be continued for at least a year, in order to prevent relapse and optimize outcome. [8] [9] [10] [11] There is partial evidence that SNRIs and other newer antidepressants are effective in PD. 80 On the one hand, relatively few of these agents have been well studied in PD, not all findings have been consistently positive, and concerns have also been raised about the safety profile of certain agents (eg, venlafaxine) in comparison with the SSRIs. 85 On the other hand, there is some evidence that more noradrenergic antidepressants may be of benefit in PD patients who have failed to respond to serotonergic antidepressants. 86 Thus SNRIs and some other newer antidepressants (for example, mirtazapine and reboxetine) can be considered as a treatment option in the pharmacotherapy of PD. 87 There is also some evidence of the efficacy of other classes of agent in panic disorder. In particular, anticonvulsant agents have been investigated for use. While early RCTs found gabapentin and carbamazepine to be of limited benefit compared with placebo, 88, 89 valproate may be effective in some patients. 90, 91 These medications can perhaps be considered as augmenting agents in treatment-refractory PD cases. However, more rigorous clinical investigation is required before they can be recommended for widespread use. 80 Underdiagnosis and undertreatment of PD remains a particular problem. Further, as above, a proportion of P h a r m a c o l o g i c a l a s p e c t s patients with PD do not respond to first-line pharmacotherapy. As always in such cases, diagnosis should be reaffirmed, and duration and dose optimized. 8 Again, while there has been relatively little rigorous work on switching to agents of a different class, this is a reasonable strategy. 37 Augmentation strategies that have been researched include the addition of pindolol. 92,-94 The addition of psychotherapy (CBT) to pharmacological treatment may also be useful in PD. [95] [96] [97] [98] [99] [100] As in the case of GAD and OCD, then, there has on the one hand been significant progress in the pharmacotherapy of PD (including the introduction of the SSRIs), while on the other hand several challenges remain (including the treatment of patients refractory to the SSRIs). Once again, psychobiological research has provided tantalizing hints of novel treatment targets for future work. Adenosine receptors may, for example, play a unique role in the pathogenesis of PD, and may provide a novel target for future treatments of PD. 101 Alternatively, work on molecular systems that appear to be involved in a number of different anxiety disorders (eg, glutamate, the HPA axis), may also lead to new treatments of PD.
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Post-traumatic stress disorder
As has been the case in several anxiety disorders, early trials for post-traumatic stress disorder (PTSD) focused on agents that had been proven effective for depression, 102 namely TCAs and MAOIs. And once more, the introduction of the SSRIs led to a series of multisite trials showing comparable efficacy but better tolerability. More recently, there has been ongoing work on the treatment of refractory cases, using other classes of agents such as atypical antipsychotics. Of particular importance has been the emergence of proof-ofprinciple trials, often grounded in animal literature. These have focused on the pharmacotherapy of PTSD prophylaxis and on the enhancement of psychotherapy for this disorder. Several TCAs have been investigated in the treatment of PTSD. [103] [104] [105] Although some trials have shown efficacy, the relatively unfavorable side effect profile of these agents means that they are not considered a first-line option in most treatment guidelines. 8, 9, 11, [106] [107] [108] [109] Similarly, although MAOIs such as phenelzine may be effective in PTSD, 110 their use remains limited by their safety and tolerability profile.
A number of SSRIs and venlafaxine have been found to be effective and safe in PTSD (Table III) . 102 Paroxetine and sertraline are FDA-approved for use in this disorder. 15 Most current guidelines therefore advocate the use of one of the SSRIs and/or SNRIs as first-line pharmacotherapy. 8, 9, 11, 106, 108, 109 The available literature suggests that a trial period of about 8 to 12 weeks should be undertaken to assess efficacy. 8, 111 Long-term studies suggest that maintenance treatment should be continued in responders for at least a year. 102, 112 Limited data exists on a number of other medication classes in PTSD. For example, the anticonvulsants lamotrigine and topiramate have been found to be effective as either monotherapy 113, 114 or augmentation strategy. 115 Once again, however, given the relative paucity of data, such agents are not considered a first-line option in the pharmacotherapy of PTSD. Limited work has been undertaken in patients not responding to initial SSRI/SNRI treatment, or in special populations such as children and adolescents. 41, 116 In treatment-refractory patients, switching to a different SSRI/SNRI can be considered, but has not been well studied. Augmentation with an atypical antipsychotic (eg. risperidone or olanzapine) has been found efficacious in some studies. [117] [118] [119] Other considerations include the addition of an anticonvulsant agent, for example topiramate. 115 Treatment guidelines emphasize the need for ongoing assessment of the risk:benefit ratio of such strategies, for example, monitoring metabolic effects. 8, 106 Animal studies of stress have given impetus to the question of whether PTSD can be prevented by early pharmacotherapy. Early proof-of-principle studies suggested that the β-blocker, propanolol, may be efficacious in this context. 120, 121 The hypothalamic-pituitary-adrenal (HPA) axis has been well-studied in both animal and human work on stress, and the administration of IV hydrocortisone in the hospital setting has been suggested useful in PTSD prophylaxis. 122, 123 However, subsequent work with propanolol and other agents has not always been supportive of the early work, 124, 125 and further research in this area remains necessary. Laboratory research also led to the hypothesis that Dcycloserine, a partial agonist at NMDA (N-methyl Daspartate) glutamate receptors, 126 may be useful in enhancing CBT in PTSD. Early proof-of-principle trials have shown promise. 127, 128 This is a particularly exciting development, as it represents that, for perhaps the first time, a translational approach in anxiety disorders has led to an efficacious new treatment. Various other molecular targets for CBT augmentation have been suggested, 12 but further work is needed to confirm the effectiveness of such approaches in the clinical context.
Social anxiety disorder
The pharmacotherapy of patients with social anxiety disorder (SAD) was given initial impetus by the finding that MAOIs are effective, but TCAs are not. As in the case of PD and OCD, this suggested that particular agents might be efficacious for particular anxiety disorders. And, once again, although the introduction of the SSRIs for SAD did not support such the hope of pharmacotherapeutic dissection, it did provide an effective and well-tolerated pharmacotherapy. Again, despite the availability of a range of medications for SAD, many patients either do not respond or remit. 129 Thus, there is an ongoing need for further work on treatment-refractory cases and novel treatment targets. Early on the MAOIs showed efficacy for SAD in a number of placebo-controlled trials. 130 In particular, phenelzine, an irreversible MAOI, was efficacious. Withdrawal rates were similar between groups with no significant difference in dropouts attributable to adverse events. ; thus although they are part of the current armamentarium, they are not typically considered first-line agents. 8, 9, 11, 135 The benzodiazepine clonazepam showed promise in the short-and long-term treatment of patients with SAD. 136, 137 However, once again, given risk:benefit considerations, benzodiazepines are not usually recommended as first-line agents for SAD. 8, 9, 11, 135 Several SSRIs have been shown to be efficacious and relatively well-tolerated in the treatment of SAD. 138, 130, 139 Both paroxetine and sertraline are FDA-approved for treatment of this disorder (Table IV) . Given the substantial evidence base indicating the efficacy and safety of SSRIs, they are typically recommended as the firstline pharmacotherapy in treatment guidelines. 8, 9, 11, 135 Of the SNRIs, venlafaxine is the best studied in SAD, where it has shown efficacy in a number of RCTs. 134 This agent is therefore considered a reasonable alternative to the use of SSRIs in a number of treatment guidelines, and is FDA-approved for such use. 8, 9, 11, 135 Current guidelines recommend that active treatment with SSRIs/SNRIs should be continued for at least a year. 8, 9, 11 This recommendation is supported by a number of placebo-controlled relapse-prevention studies. 139 Several anticonvulsant agents have also been studied in SAD. 134, 140, 141 Both gabapentin 88 and pregabalin, for example, have shown efficacy compared with placebo. However, neither agent is registered for the treatment of SAD, and additional studies are required before their routine use can be recommended. A limited number of studies have investigated atypical antipsychotics in SAD. 142 A consideration of risk:benefit ratio suggests that these agents should not yet be viewed as a first-line option in SAD. 135 However, their role as an augmenting strategy in treatment-refractory cases perhaps deserves additional consideration. Up to 50% of SAD patients do not respond to initial pharmacological treatment. 129 As always, diagnosis, dose, and duration should be optimized. 36, 135 Relatively small switch studies have shown the benefit of treatment with a different agent with proven efficacy, for example venlafaxine 143 or phenelzine. 144 Augmentation strategies that may be considered include the use of buspirone, 145 clonazepam, 146 and combined pharmacological and psychological therapy. 133, 147 There has again been interest in the possibility that Dcycloserine may be useful in enhancing CBT. An early proof-of-principle trial indicated that this agent was significantly more effective than placebo in enhancing CBT. 148 Other targets for CBT augmentation have also been suggested, 12 and this seems an exciting area for future investigation. 149 As in the case of other anxiety disorders, there is significant scope for studies that incorporate genetic and imaging methods into pharmacotherapy studies, 150, 151 aiming ultimately at individualizing treatment approaches in SAD.
Conclusion
The glass of pharmacotherapy of anxiety disorders studies seems both half-full and half-empty. On the one hand, there is a good number of randomized clinical trials of anxiety disorders; these have been extensively reviewed and meta-analyzed, and they include a particularly large and persuasive set of studies showing efficacy and relatively good tolerability of the SSRIs in the major anxiety disorders. Secondary analyses of such datasets have informed questions such as optimal definition of response and remission, optimal dose and duration, and comparative efficacy of different agents. 736, 152 Innovative questions, such as the use of pharmacotherapy for prophylactic purposes, have begun to be studied.
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On the other hand, a significant proportion of patients with anxiety disorders fail to be diagnosed and treated, 1 or to respond to first-line agents, and there is a limited database of efficacy or effectiveness studies to guide treatment in such cases. Pharmacotherapy of children and adolescents, and of the elderly with anxiety disorders are other areas where some recommendations can be made, but where much further work is needed. 153, 154 There is a significant research gap in that most studies have been undertaken at academic tertiary centers in high-income countries for registration purposes, while worldwide the vast majority of the clinical burden of anxiety disorders manifests in low-and middle-income countries in the community and in primary care. Fortunately, although much remains to be learned about the pathogenesis of the anxiety disorders, progress has been made, and such work has led to some of the first bedside neuroscience interventions ever to have emerged directly from the bench. 127, 155 Further such work should be encouraged; there is significant scope for merging new neuroscience methodologies, for example, imaging and gene expression 156, 157 with pharmacotherapy studies in order to help find new treatment targets, and in order to better personalize future treatment strategies. Funding for such work may, however, require both professionals and lay advocates to emphasize both the untreated burden of anxiety disorders, as well as the rich scientific opportunities that exist. ❏ P h a r m a c o l o g i c a l a s p e c t s 
